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Background: Opioid use for chronic non- cancer pain (CNCP) is complex. In the 
absence of pan- European guidance on this issue, a position paper was commissioned 
by the European Pain Federation (EFIC).
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1 |  INTRODUCTION
In 2017, the European Pain Federation (EFIC) published 
a position paper on appropriate opioid use in chronic pain 
management (O'Brien et al., 2017). The position paper did 
not differentiate between management of chronic cancer and 
non- cancer pain (CNCP). The importance of opioids in the 
management of cancer pain and in palliative care is interna-
tionally accepted although the amount and quality of evi-
dence around the use of opioids for treating cancer pain is 
disappointingly low (Wiffen et al., 2017).
The opioid crisis in North America (DeWeerdt, 2019) led 
to an update of the Canadian guideline on opioids for CNCP 
(Busse et al., 2017; Furlan et al., 2010) and to a guideline from 
the United States (US) Centers for Disease Control (CDC) 
(Dowell et  al., 2016), which focused on harm reduction in 
relation to opioid prescribing for CNCP. Furthermore, sev-
eral US authors have discussed their concerns that the opioid 
crisis reflects shortcomings of the North American health 
care systems (Dasgupta et al., 2018; Sullivan & Howe, 2013).
Although European countries are far from the opi-
oid crisis in North America (Chenaf et  al.,  2019; Häuser 
et al., submitted; Kalkman et al., 2019; National Records 
of Scotland, 2018; Rosner et al., 2019), there are increas-
ing concerns about the safety of long- term opioid ther-
apy (LTOT) for patients with CNCP (Ballantyne,  2016). 
Therefore, EFIC commissioned a Task Force (TF) to up-
date their position paper on appropriate opioid use spe-
cifically for CNCP and to separate it from cancer pain. In 
2019, standards for the management of cancer- related pain 
across Europe from the EFIC Task Force on Cancer Pain 
were published (Bennett et al., 2019). By including other 
Methods: The clinical practice recommendations were developed by eight scientific 
societies and one patient self- help organization under the coordination of EFIC. A 
systematic literature search in MEDLINE (up until January 2020) was performed. 
Two categories of guidance are given: Evidence- based recommendations (supported 
by evidence from systematic reviews of randomized controlled trials or of obser-
vational studies) and Good Clinical Practice (GCP) statements (supported either by 
indirect evidence or by case- series, case- control studies and clinical experience). The 
GRADE system was applied to move from evidence to recommendations. The rec-
ommendations and GCP statements were developed by a multiprofessional task force 
(including nursing, service users, physicians, physiotherapy and psychology) and 
formal multistep procedures to reach a set of consensus recommendations. The clini-
cal practice recommendations were reviewed by five external reviewers from North 
America and Europe and were also posted for public comment.
Results: The key clinical practice recommendations suggest: (a) first optimizing estab-
lished non- pharmacological treatments and non- opioid analgesics and (b) considering 
opioid treatment if established non- pharmacological treatments or non- opioid analge-
sics are not effective and/or not tolerated and/or contraindicated. Evidence- and clini-
cal consensus- based potential indications and contraindications for opioid treatment are 
presented. Eighteen GCP recommendations give guidance regarding clinical evaluation, 
as well as opioid treatment assessment, monitoring, continuation and discontinuation.
Conclusions: Opioids remain a treatment option for some selected patients with 
CNCP under careful surveillance.
Significance: In chronic pain, opioids are neither a universal cure nor a universally 
dangerous weapon. They should only be used for some selected chronic noncancer pain 
syndromes if established non- pharmacological and pharmacological treatment options 
have failed in supervised pain patients as part of a comprehensive, multi- modal, multi- 
disciplinary approach to treatment. In this context alone, opioid therapy can be a useful 
tool in achieving and maintaining an optimal level of pain control in some patients.
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European health professional societies, the paper was re-
named as European Clinical Practice Recommendations 
(ECPRs).
This paper concerns opioids for CNCP and aims to pro-
mote the responsible use of opioids for CNCP by:
• discussing the role of opioids in the management of 
CNCP.
• identifying potential indications, contraindications and ad-
vice for discontinuation of opioids.
• providing recommendations for Good Clinical Practice 
(GCP; e.g. dosing; selection of opioids; monitoring side 
effects).
• discussing the role of opioids in specific patient populations.
• giving recommendations for the management of specific 
adverse events of opioids.
1.1 | Scope
The purpose of the ECPRs is to support appropriate deci-
sion making and, if warranted, appropriate prescribing of 
opioids for patients of any age with chronic (persistent or 
recurrent >3 months) noncancer pain. The target audience 
includes:
• all health care professionals (physicians, psychologists, 
nurses, occupational therapists, physiotherapist, pharma-
cists) supporting patients with CNCP.
• those who take opioids (patients) and their significant 
others.
• those who create opioid prescribing policy.
These clinical practice recommendations discuss all 
oral and transdermal opioids which can be prescribed for 
chronic pain management in Europe (buprenorphine, co-
deine, fentanyl, hydrocodone, hydromorphone, methadone, 
morphine, oxycodone, polamidone, tilidine), including 
opioids with a two- way mode of action (tapentadol and tra-
madol). Combination products of opioids with other anal-
gesics, such as paracetamol, are not covered. The ECPR is 
focused on LTOT for CNCP. Therefore, it does not address 
the management of acute or subacute pain (<4  weeks) 
treatment (including acute pain episodes of chronic dis-
eases such as sickle cell disease), end of life care, or the 
use of opioids for non- painful conditions such as opioid 
use disorder.
Definitions of LTOT vary widely. Most studies define 
long- term as ≥12 weeks of opioid use (Karmali et al., 2020). 
Based on study duration of RCTs, we have made a classifi-
cation for duration of opioid therapy for evidence- based rec-
ommendations for potential indication of opioids: short- term 
(4– 12 weeks), intermediate- term (13– 26 weeks), long- term 
(>26 weeks).
1.2 | Disclaimer
The ECPRs are not intended to contradict disease- specific 
evidence- based guidelines. They are expert consensus state-
ments rather than a guideline and incorporate the expertise 
of the TF membership. The TF members acknowledge the 
conclusions of robust evidence- based guidelines but the 
clinical practice recommendations recognize that individual 
responses to therapy may differ from average responses de-
scribed in evidence- based guidelines. The ECPRs represent 
a consensus statement of healthcare professionals who work 
with people with pain provides an experienced perspective, 
acknowledging the evidence, to support clinical decision 
making.
The ECPRs do not represent a regulation of action or 
omission, which has been agreed by a legally legitimate in-
stitution, fixed in writing and published. It is not binding for 
the legal area of an institution and will not result in defined 
sanctions, if not followed. Recommendations only become 
clinically effective if the strength of recommendation is con-
sidered and integrated in individual patient care, including 
shared- decision making with patients. The decision as to 
whether a certain strength of recommendation should be fol-
lowed must be made by physicians, considering the circum-
stances of individual patients and the available resources.
2 |  METHODS
2.1 | Task force membership
The TF included 17 members (6 female) from nine European 
countries (North, Central, East and South Europe and UK). 
Nine delegates were nominated by EFIC's board. The board 
selected delegates who advocate and who are critical with 
the use of opioids for CNCP. Seven delegates representing 
members of the European Pain Forum (https://europ eanpa 
infed erati on.eu/advoc acy/curre nt- proje cts/europ ean- pain- 
forum/) volunteered to contribute. These delegates were se-
lected because of their clinical and/or scientific expertise. 
One delegate of the Pain Alliance Europe (PAE) participated 
as a patient representative. The TF included most health care 
professions (medicine, nursing, physiotherapy, psychology) 
caring for patients with chronic pain. The medical special-
ties of the physicians were anesthesiology, gastroenterology, 
general practice/family medicine, general internal medicine, 
neurology, pain medicine, palliative care, physical and reha-
bilitation medicine, psychiatry, psychosomatic medicine (see 
Table 1).
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2.2 | Managing conflicts of interest
All TF members declared any potential conflicts of inter-
est (COIs) before the start of the update using the Form 
for Disclosure of Potential Conflicts of Interest from the 
International Committee of Medical Journal Editors (http://
www.icmje.org/confl icts- of- inter est/). Potential COIs were 
independently evaluated by two representatives of EFIC 
(Sam Kynman, Executive Director and Prof. Hans Georg 
Kress, Chair of Ethics Committee), who did not participate in 
the development of this paper. Discrepancies were resolved 
by consensus. The degree of financial COIs with pharmaceu-
tical companies producing opioids was classified into none, 
slight, moderate, high, defined as follows:
• None: No interaction.
• Slight: Only honoraria for lectures.
• Moderate: Advisory board; study support.
• High: Patent; employee of a pharmaceutical company.
Twelve members of the TF had no COIs, including the 
three TF chairs (Häuser, Krcevski- Škvarč, & Vowles). Five 
members had moderate financial COIs (Drewes, Morlion, 
O'Brien, Pogatzky- Zahn, Tölle).
Secretarial support for the drafting of this position paper 
came from EFIC. The funding of EFIC is detailed in its most 
recent annual reports which can be found on the EFIC web-
site https://europ eanpa infed erati on.eu/how- we- work/annua 
l- repor t/. The funding of PAE is detailed in https://pae- eu.
eu/activ ities/.
2.3 | Key questions
The key questions to be addressed were defined by a Delphi 
round of theTF. Four recent national (Canada, France, 
Germany, USA; Busse et al., 2017; Dowell et  al.,  2016; 
Moisset & Martinez,  2016; Häuser et  al.,  2020) guidelines 
on opioids for CNCP were provided to the members of the 
TF by the evidence synthesis team to inform the process. The 
key questions are outlined in Supplementary Material 1.
2.4 | Search strategy
For the review of potential opioid indications and contrain-
dications, we focused on systematic reviews (with or with-
out meta- analysis) of randomized controlled trials (RCTs) of 
opioids for CNCP with at least 4 weeks double- blind dura-
tion and open label extensions studies of these trials with at 
least 6 months duration and evidence- based guidelines con-
cerned with the management of CNCP. The evidence synthe-
sis team (Häuser, Welsch) conducted the searches. PubMed 
was searched on 11 February 2020 (from 2015) with the 
search terms [‘opioid’ AND ‘chronic pain’ AND ‘systematic 
review’]. PROSPERO was searched 8 March 2020 with the 
search terms [‘opioids’ and ‘chronic non- cancer pain’].
For the section on special situations, we conducted a selec-
tive search of literature in PubMed in April 2020 with the search 
term [‘opioids’] and the respective term of the GCP statement.
The literature for the ECPRs was selected by the members 
of the evidence synthesis team. The reference lists of the sys-
tematic reviews and guidelines selected were also considered 
for the recommendations and clinical practice statements of the 
position paper. Discrepancies were resolved by consensus.
2.5 | Summary of evidence
The patient representative was involved in defining the key 
questions, providing recommendations and good clinical 
practice statements, and the evaluation of the patient version 
of the clinical practice recommendations.
The evidence synthesis team created evidence summaries 
based on the selected systematic reviews. The selection of out-
comes of interest was based on the recommendations of the 
ACTINPAIN writing group of the International Association 
for the Study of Pain's (IASP) Special Interest Group on 
Systematic Reviews in Pain Relief (Moore et  al.,  2010) 
and the guideline on the clinical development of medicinal 
products intended for the treatment of pain of the European 
Medicines Agency (2017). These outcomes included:
1. Pain relief from baseline of 30% or greater
2. Patient global impression to be much or very much 
improved
3. Disability
4. Drop out rates to adverse events
5. Serious adverse events
6. Death
7. Non- medical use/dependence
We used the systematic review with the most recent search 
of literature or the most studies included in the analyses. If 
reported, the GRADE system was used for the evidence sum-
maries to provide a description of benefits and harms, along 
with a rating of the certainty of the evidence on an outcome- 
by- outcome basis (Langendam et al., 2013). If no GRADE 
rating was available, we used the UpToDate® rating of the 
quality of evidence (UptoDate, 2020a, 2020b).
2.5.1 | Patient preferences
Pain Alliance Europe (PAE) conducted a survey with some 
member countries (Spain, Romania, Belgium, UK, Sweden 
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and Finland) on the importance of potential positive and 
negative effects taking a new medication for the chronic 
pain management from 22 May to 2 June 2020. The poten-
tial positive and negative effects of medications (related to 
opioids) were selected by three TF members (two physi-
cians, one patient representative). In total, 131 PAE mem-
bers participated (78% females). The details of the patient 
survey are outlined in Supplementary Material 2. Important 
or very important positive and negative effects were rated 
as follows:
• Positive effects
a. Pain relief of 50% or more: 74% of the respondents.
b. Pain relief of 30% or more: 92% of the respondents.
c. Improvement of daily functioning: 91%.




c. Sexual problems: 45%.
In addition, a search in PubMed [‘patient preferences’ 
AND ‘opioids’ AND ‘CNCP’) in 6 February 2020 produced 
6 hits. We found one systematic review, which ranked pain 
relief, nausea and vomiting as highly significant negative 
outcomes across studies. When considered in the studies, the 
adverse effect of personality changes was rated as equally im-
portant. Constipation was assessed in most studies and was 
an important outcome, but secondary to pain relief, nausea 
and vomiting. The only two studies that evaluated addiction, 
found it less important to patients than pain relief (Goshua 
et al., 2018).
2.6 | Development of recommendations and 
GCP statements
This paper includes two categories of guidance: Evidence- 
based recommendations (supported by evidence from sys-
tematic reviews of RCTs or of observational studies) and 
GCP statements (supported by either indirect evidence or 
by single RCTs, case- series, case- control studies or clini-
cal experience). We applied the GRADE system to move 
from evidence to recommendations if systematic reviews 
with GRADE ratings were available (Andrews et al., 2013). 
We used UptoDate rating of quality of evidence, if system-
atic reviews with GRADE ratings were not available (see 
Table 2). All members of the TF completed the Uptodate® 
Grading tutorial (https://www.uptod ate.com/home/gradi ng- 
tutor ial#).
Evidence- based recommendations could be made ‘for’ or 
‘against’. The strength of a recommendation could be ‘strong’ 
or ‘weak’ (see Table 3). For a strong recommendation, we 
noted, ‘We recommend’. For a weak recommendation, we 
noted, ‘We suggest’. Similarly, GCP statements could be 
made ‘for’ or ‘against’ with the terms ‘should be considered’ 
(valid for nearly all patients) and ‘can be considered’ (valid 
for the majority of patients) (see Table 3).
The TF is aware that there are controversies or disparities 
in interpretation of the evidence (e.g. of the RCTs for CLBP). 
Quality rating Rationale
Strong Consistent evidence from well performed randomized, controlled trials or 
overwhelming evidence of some other form. Further research is unlikely 
to change our confidence in the estimate of benefit and risk.
Moderate Evidence from randomized, controlled trials with important limitations 
(inconsistent results, methodologic flaws, indirect or imprecise), or very 
strong evidence of some other form. Further research (if performed) is 
likely to have an impact on our confidence in the estimate of benefit and 
risk and may change the estimate.
Low Evidence from observational studies, unsystematic clinical experience, or 
from randomized, controlled trials with serious flaws. Any estimate of 
effect is uncertain.
Note: The general categories that lower the quality of evidence from RCTs are:
Methodologic problems likely to cause bias:
• Inconsistent results
• Indirectness of evidence
• Few observed events
The factors that may raise the quality of evidence from observational studies are:
• Large magnitude of effect
• All plausible biases would reduce a demonstrated effect
• Dose- response gradient
T A B L E  2  Rating of the quality 
of supporting evidence according to 
UptoDate®
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Therefore, our evidence- based recommendations are based 
on clinical experience, too.
2.7 | Consensus- finding procedure
The evidence- based recommendations and GCP statements 
were initially prepared by the three chairs of the TF (Häuser, 
Krcevski- Skvarc, & Vowles). These were then discussed, 
modified and finalized by the TF in seven Delphi rounds. 
The individual members of the TF then voted online from 1 
to 12 June 2020. The group held a final web- based consen-
sus conference on 13 June 2020. All TF members partici-
pated in the online voting and all but one in the web- based 
consensus- conference. In this conference, all statements and 
recommendations which did not reach a consensus of >90% 
in the online vote were discussed and modified if necessary 
with the aim to increase the strength of consensus. For both 
voting procedures TF members had three options: Agree, 
disagree or abstention (due to lack of expertise). Abstention 
votes were not included in calculations regarding the strength 
of consensus.
Strength of consensus was classified as follows: strong 
consensus: >95% agreement; consensus: 75%– 95% 
agreement; majority: 50%– 75% agreement; no consensus: 
≤50% agreement.
The strength of consensus was assessed in two ways: With 
and without the votes of the members with moderate COIs. In 
the document, the strength of consensus for every recommen-
dation and clinical practice statement is reported as follows in 
brackets: (votes of all TF members; votes of all TF members 
without COIs).
2.8 | External reviews
The draft ECPR document was sent to five individuals with 
expertise in opioids for chronic pain, each of whom provided 
an open review. These individuals included Jane Ballantyne 
(USA), Andrea Furlan (Canada), Cathy Stannard (UK), 
Rainer Sabatowski (Germany) and Mark Sullivan (USA). 
These experts were asked to identify any omissions of impor-
tant topics, comment regarding evidence- based recommenda-
tions or GCPs, provide alternative suggestions if necessary, 
and comment on methods where important. The heads of the 
TF drafted replies to the reviewers and suggested changes to 
evidence- based recommendations, GCP statements and com-
ments in consensus. All suggestions for modifications of this 
paper were discussed by the TF.
Based on the comments of the reviewers, five GCP state-
ments (two on the role of opioids; one on short- versus long 
acting opioids; one on intake scheme; one on opioid- induced 
hyperalgesia) were changed with regards to content. One 
new GCP statement on opioid tapering was added. A Delphi 
round of the TF to assess the strength of consensus of these 
five modified GCP statements was conducted. The wording 
of the strength of recommendation for GCP statements was 
changed. The wording, but not the content, of eleven GCP 
statements was changed. Twenty- seven comments were also 
expanded. In the sections ‘background, scope, disclaimer’ six 
amendments were made.
Twelve public comments (11 from health care profession-
als, one from a pharmaceutical company producing an opi-
oid) were received. All public commentators declared their 
financial conflicts of interest (available on request): All com-
ments were reviewed and answered by the TF chairs based on 
consensus. The answers were discussed by the TF members. 
Seventeen comments were modified (wording, supplements) 
based on the comments of the health professionals. Based 
on the comment of the pharmaceutical company, one sup-
plement was made in the section scope and ten comments 
were modified (wording, supplements). We followed one of 
six suggestions of the company, to mention their product in 
the comment.
The changes in the ECPRs based on the comments of the 
reviewers and the public commentators can be provided on 
request.
T A B L E  3  How to use and understand the recommendations and 
good clinical practice statement of the position paper
This position paper provides prescribers and patients with a basis 
for decisions about using opioids to manage chronic noncancer 
pain. Prescribers, patients and other stakeholders – particularly 
regulatory agencies or the courts – should not view the 
recommendations and good clinical practice statements in this 
guideline as absolute. No guideline can account for the unique 
features of patients and their clinical circumstances; this guideline 
is not meant to replace clinical judgment.
A strong recommendation means that benefits clearly outweigh 
risks and burdens or vice versa. It indicates that all or almost all 
fully informed patients would choose the recommended course 
of action, and indicate to clinicians that the recommendation is 
appropriate for almost all patients.
A weak recommendation means that benefits, risks, and burdens 
are closely balanced or uncertain. It indicates that the majority 
of informed patients would choose the suggested course of 
action, but an appreciable minority would not. With weak 
recommendations, clinicians should recognize that different 
choices will be appropriate for individual patients, and they should 
help patients arrive at a decision consistent with their values and 
preferences.
The term ‘Should be considered’ in a good clinical practice 
statement means, that the good clinical practice statement is 
appropriate for almost all patients.
The term ‘Can be considered’ in a good clinical practice statement 
means, that the good clinical practice statement is appropriate for 
the majority of patients.
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2.9 | Final approval
This ECPRs were approved by the board of EFIC and the 
boards of nine participating member societies of the Pain 
Forumn and the European Pain Alliance.
2.10 | Publication and dissemination
The ECPRs were submitted to the European Journal of Pain in 
two parts. Part one covers the role of opioids in the manage-
ment of CNCP, potential indications and contraindications, 
and GCP of opioid use. Part two covers special situations, in-
cluding non- medical use and dependence (Krcevski- Škvarc 
et al., 2021). A short version for health care professionals 
will be designed by the TF and be available on the webpage 
of EFIC. A version for lay persons of the position paper will 
be developed with PAE.
3 |  RESULTS
3.1 | Good clinical practice statements and 
recommendations
3.1.1 | Part 1: Role of opioids in the 
management of chronic noncancer pain
1. Optimization of non- opioid treatment. Before consid-
ering opioid treatment, we first suggest optimizing non- 
pharmacological treatments (e.g. exercise, physiotherapy, 
psychological therapies) and considering non- opioid an-
algesics. Weak recommendation, strong consensus (16/16; 
11/11).
Comment: Optimization of non- pharmacological 
therapies should include interdisciplinary multimodal 
pain therapy (Kaiser et  al.,  2017) – if available – and 
– in selected patients – invasive procedures such as 
neuromodulation.
2. When to consider opioids. We suggest considering a 
trial of opioids if established non- pharmacological treat-
ments and established non- opioid analgesics are:
• Not effective and/or
• Not tolerated and/or
• Contraindicated
• Not available
**Established = Guideline recommended or – if not avail-
able – current medical standard.
Weak recommendation, strong consensus (15/15; 10/10).
Rationale: We are not aware of any interdisciplinary 
evidence- based guideline which recommends opioids 
as a first line treatment for any type of CNCP. Non- 
pharmacological therapies such as exercise and psycho-
logical therapies have been recommended as first line 
therapies for common CNCP syndromes such as low 
back (Oliveira et  al.,  2018) or osteoarthritis pain (Gay 
et al., 2016). Although non- pharmacological approaches 
for chronic pain have only small effect sizes with NNTs 
ranging from 4 to above 10 (Skelly et  al.,  2018), they 
should be optimized first given that the efficacy of drug 
therapies for CNCP syndromes such as low back pain 
is limited too and associated with potentially significant 
side effects. Anticonvulsants have been recommended as 
first line therapy for neuropathic pain (Finnerup et al., 
2015). Potential serious adverse events such as over-
dose death and addiction by opioids (Busse et al., 2012), 
gastrointestinal bleeding (Castellsague et al., 2012) and 
cardiovascular events by NSAIDs (Bally et  al.,  2017), 
non- medical use of gabapentinoids (Schjerning 
et al., 2016), and liver failure by antidepressants (Darr & 
Sussman, 2020) must be considered.
Evidence summary (for details see Supplementary 
Material 3): PICO (Patient, Intervention, Comparator, 
Outcome): What is the efficacy, tolerability and safety of opi-
oids compared to non- opioid analgesics for CNCP in RCTs of 
at least 4 weeks duration?
A systematic review of RCTs comparing opioids with 
non- opioid analgesics found that nonopioid analgesics were 
superior to opioids in terms of improvement of physical func-
tion and tolerability in short- term (4– 12 weeks) therapy of 
neuropathic, low back and osteoarthritis pain (moderate qual-
ity UptoDate evidence) (Welsch et al., 2015). These results 
are in accordance with the findings of the recent review on 
behalf of the US Agency for Healthcare Research and Quality 
(Chou et al., 2020).
3. Selection of medications: The selection of medications 
should consider the type of CNCP, the comorbidities of the 
patient, contraindications, patient preferences, benefits and 
harms of previous therapies and the benefit- risk ratio of 
available pharmacological alternative treatment options. 
Good clinical practice statement. Strong Consensus (16/16; 
11/11)
Comment: There is marked inter- individual variation 
in response/tolerability of all analgesics including various 
opioids that is not predicatable prospectively. A number of 
factors may influence the clinician's choice of opioid when 
initiating treatment including:
• Clinician's preference, often based on familiarity, availabil-
ity and cost
• Required route of delivery – e.g. oral (preferrred) but in 
some instances a transdermal delivery may be selected for 
ease of administration and reducing oral medication bur-
den etc.
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a. All potential indication cited below should only be con-
sidered in the view of the recommendations on the role 
of opioids in the management of CNCP.
b. CNCP is a descriptive term which covers many painful 
medical conditions which vary in clinical presentation 
and underlying pathophysiological mechanisms, includ-
ing the absence of identifiable underlying mechanism. 
The IASP- WHO joint task force which developed the 
new concepts of the chronic pain classification system 
has suggested a distinction between chronic primary pain 
(disease of its own right) and chronic secondary pain 
(pain as a symptom of an underlying disease). The main 
pathophysiological mechanism of primary pain syn-
dromes is nociplastic pain and of chronic secondary pain 
syndromes nociceptive and/or neuropathic pain (Nicholas 
et al., 2019; Treede et al., 2019; Trouvin & Perrot, 2019). 
Nociplastic pain is defined by pain that (1) arises from 
altered nociception despite no (2) clear evidence of actual 
or threatened tissue damage causing the activation of pe-
ripheral nociceptors or (3) evidence for disease or lesion 
of the somatosensory system causing the pain (Kosek 
et al., 2016).
The distinction between primary and secondary pain can be 
an oversimplification. In some patients with chronic second-
ary pain, such as osteoarthritis or post- injury pain, nociplas-
tic mechanisms play a role (Moore et al., 2020; Woolf, 1983). 
Ongoing nociceptive input, for example, by low grade joint 
inflammation, may play a role in so- called secondary (comor-
bid) fibromyalgia (Fitzcharles et al., 2018) which is regarded 
to be a prototype of a nociplastic pain syndrome (Nicholas 
et al., 2019).
Because of the diversity of CNCP syndromes, the up-
dated position paper follows the approach of the French 
and German guideline (Häuser et  al.,  2020; Moisset & 
Martinez, 2016), to split CNCP into different clinical enti-
ties with regards to potential indications and contraindica-
tions of opioids.
4.1 We suggest considering opioids for the chronic sec-
ondary pain syndromes listed below. Weak recommendation
Evidence summary (for details see Supplementary 
Material 4):
PICO: What is the efficacy, tolerability and safety of 
opioids compared to placebo in patients of any age with 
CNCP?
There is low to very low quality GRADE evidence from 
21 RCTs of 4– 15 weeks with 7,650 participants that opioids 
are superior in reducing pain and disability, inferior in tol-
erability and not different in safety compared to placebo for 
CLBP- pain (Petzke et  al.,  2020) (Supplementary Materials 
1 and 2).
There is low to very low quality GRADE evidence from 
22 RCTs of 4– 26 weeks with 8,942 participants that opioids 
are superior in reducing pain and disability, inferior in tol-
erability and not different in safety compared to placebo for 
OA- pain (Welsch et al., 2020).
There is low to very low quality GRADE evidence 
from 16 RCTs of 4– 12 weeks with 2,199 participants that 
opioids are superior in reducing pain and disability, infe-
rior in tolerability and not different in safety compared to 
placebo for some neuropathic pain syndromes (Sommer 
et al., 2020).
There is very low quality GRADE evidence from 15 open 
label extension studies of up to 4 years duration with 3,590 
participants that in self- selected patients with chronic low 
back, neuropathic and OA pain, reductions of pain and dis-
ability can be maintained. Drop out rate due to adverse events 
and deaths increase with study duration (Bialas et al., 2020).
The low rate of serious adverse events in RCTs with opi-
oids is in sharp contrast to the results of observational studies 
in North America which have demonstrated important risks of 
nonfatal and fatal unintentional overdose, very frequent phys-
ical dependence and frequent addiction (Busse et al., 2017). 
Routine clinical care data from some European countries did 
not show signals of an opioid epidemic (Bedene et al., 2019; 
Chenaf et al., 2019; Kalkman et al., 2019; Rosner et al., 2019).
Potential explanations of these divergences are as follows:
a. Most RCTs excluded patients with current or a history 
of substance abuse and with major medical diseases. 
These (relative) contraindications for opioids might have 
been neglected in routine medical care in North America. 
Opioids have been prescribed to the most vulnerable 
part of the population (unemployment, poverty, mental 
health problems) (deWeerdt,  2019).
b. The surveillance of patients in the context of clinical stud-
ies is closer than the one in routine clinical care.
c. There are differences in the health care systems be-
tween North America and Europe (e.g. availability 
of non- pharmacological treatments; expectations of 
patients to get medication prescription; financial ben-
efits by increasing the number of patients by opioid 
prescriptions).
d. Most RCTs did not systematically assess non- medical use 
and dependence or opioid use disorder and therefore may 
have underestimated their prevalence.
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4.2. Opioids can be considered for the chronic second-
ary pain syndromes listed below. Good clinical practice 
statements
Preliminary remark: A risk benefit analysis before em-
barking opioid therapy for the diagnoses listed below is 
necessary.
Clinical entity (ICD- 10 code) Quality of evidence (GRADE) Strength of Consensus
Chronic low back pain with predominant nociceptive and/or 
neuropathic pain mechanismsa (M42.16- M41.19, M42.90, 
M42.96- 99, M43.0, M43.1, M47.26, M47.27, M47.29, M47.86, 
M47.87, 47.88, M47.99, M48.06, M48.2, M54.16, M54.5, 
M55.3, M.99.33; M99.43, M99.53)
Low Consensus (16/17; 11/15)
Chronic osteoarthritis pain (M15- 19) Very low to low Consensus (13/14; 8/9)
Chronic painful diabetic polyneuropathy (G 63.2) Very low Consensus/Majority (11/14; 6/9)
Postherpetic neuralgia (B02.2) Very low Consensus/Majority (11/14; 6/9)
a Unspecific chronic low back pain with predominant nociplastic pain mechanisms is much more frequent than specific chronic low back pain with predominant 
nociceptive and/or neuropathic pain mechanisms (Maher et al., 2017). As outlined in the section ‘Potential contraindications’, opioids are not indicated for unspecific 
low back pain 





statement Strength of Consensus
Chronic pain after spinal cord injury (S24)a Moderateb Can be considered Consensus (11/13; 6/8)
Chronic non- diabetic polyneuropathy pain (G60- 64)a Moderatec Can be considered Consensus (11/12; 6/7)
Chronic phantom limb pain (G54.6)a Moderateb Can be considered Consensus/Majority (10/12; 5/7)
Chronic radicular pain (M54.1)a Moderatec Can be considered Consensus (11/12; 6/7)
Chronic pain in rheumatoid arthritis (M06.- )a Moderateb Can be considered Consensus (13/13; 8/8)
Chronic pain in Parkinson's disease (G20, 21)a Moderateb Can be considered Consensus (12/13; 7/8)
Chronic pain in restless legs syndrome (G25)a Moderateb Can be considered Consensus (11/12; 6/7)
Chronic pain due to brain lesions (e.g. status post thalamic 
stroke, multiple sclerosis)
Lowd Can be considered Consensus (10/11; 5/6)
Chronic pain due to complex regional pain syndrome 
(CRPS), types I and II (G90.5, G90.6)
Lowd Can be considered Consensus (12/13; 7/8
Chronic secondary headache (e.g. after subarachnoidal 
haemorrhage) (G44.8)
Lowd Can be considered Consensus (10/11; 5/6)
Chronic osteoporosis pain (e.g. new vertebral body fractures) 
(M80.- )
Lowd Can be considered Strong Consensus (13/13; 8/8)
Chronic pain due to other inflammatory rheumatic 
diseases except rheumatoid arthritis (e.g. systemic lupus 
erythematosis, seronegative spondylarthritis) (M45- M49)
Lowd Can be considered Strong Consensus (12/12; 7/7)
Chronic postsurgical pain (e.g. post- thoracotomy, post- 
sternotomy, and postmastectomy syndrome, and after 
abdominal, facial or hernia surgery) (T80- 88)
Lowd Can be considered Consensus (11/13; 6/8)
Chronic pain due to ischemic or inflammatory arterial 
occlusive disease (I70- I79)
Lowd Can be considered Strong Consensus (11/11;6/6)
Chronic pain due to grade 3 and 4 decubitus ulcers (L 89) Lowd Can be considered Strong Consensus (13/13; 8/8)
Chronic pain due to fixed contractures in nursing- dependent 
patients (M67)
Lowd Can be considered Consensus (10/11; 5/6)
Chronic posttraumatic trigeminal neuropathy (G 50.9) Lowd Can be considered Consensus (11/13; 6/8)
Chronic pelvic pain by extensive adhesions (N73.6) and/or 
extensive and /or infiltrating endometriosis (N80.x)
Lowd Can be considered Consensus/Majority (10/12; 5/7)
a See Supplementary Material 5. b One RCT available. c Two RCTs available. d No RCT available; expert Consensus. 
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Rationale: Opioids achieve improvements of pain and 
function compared to placebo at the cost of a lower tolera-
bility in chronic low back and osteoarthritis pain and in some 
neuropathic pain syndromes. In the context of RCTs and 
close clinical surveillance, opioids can be considered reason-
ably safe.
For all other medical conditions with nociceptive and/
or neuropathic pain mechanisms, the evidence for the use of 
opioids is based on single RCTs for some neuropathic pain 
syndromes and on clinical experience for all other medical 
conditions.
Evidence summary (see Supplementary Material 5):
5. Potential contraindications: Opioids should not be con-
sidered for primary pain syndromes. Good clinical practice 
statement
Rationale: For primary pain syndromes: (a) Our system-
atic search found only one RCT each with tramadol (Russell 
et al., 2000) and tramadol/paracetamol (Bennett et al., 2003) for 
a nociplastic pain syndrome (FMS). Tramadol has an additional 
mode of action (serotonine and noradrenaline reuptake inhibitor) 
which might explain the efficacy found (Walitt et al., 2016). (b) 
Cohort studies have demonstrated that opioid use is associated 
with a negative clinical outcome in migraine (Ashina,  2019; 
Minen et al., 2014) and fibromyalgia (Fitzcharles et al., 2013). 
(c) Guidelines discourage the use of opioids, for example for 
IBS (Drossman, 2019), fibromyalgia (MacFarlane et al., 2017) 
or migraine (American Headache Society, 2019). (d) Patients 
with primary pain syndromes may be less responsive to opioids 
due to higher endogenous opioid levels and more susceptible to 
worsening of hyperalgesia by opioids (Toubia & Khalife, 2019).
6. Controversial issues
The TF could not reach consensus regarding the potential 
indications or contraindications of opioids for pain manage-
ment in chronic pancreatitis and chronic inflammatory bowel 
disease (mainly Crohn's disease). There was a consensus that 
opioids should only be used in selected patients after interdis-
ciplinary specialist assessment as part of a multimodal treat-
ment approach and with close surveillance.
Chronic pancreatitis: In one RCT comparing morphine 
and fentanyl, both medications did not significantly reduce 
pain and disability (Niemann et al., 2000). In US cohort stud-
ies, opioid use was associated with opioid use disorder (Bilal 
et al., 2019). According to the clinical experience, up to 25% 
of patients can experience pain relief associated with opioid 
use (Drewes et al., 2017). Therefore, opioids can be used in 
selected patients under close surveillance for restricted time 
following the same recommendations as used for other pain 
syndromes. As many patients have postprandial pain or in-
termittent worsening of the background pain, treatment with 
immediate release opioids for shorter periods is likely better 
than controlled release opioids that may carry a higher risk 
of dependency. However, about 50% of patients have a his-
tory of alcohol use disorder (Olesen et al., 2019) and about 
20% continue to have excess alcohol consumption (Olesen 
Medical condition (ICD- 10 code)






Primary headache (Migraine, tension headache) (G43.x, G44.0, 
G44.2, G44.8)
Low Should not be considered Consensus/Strong 
Consensus (15/16; 
11/11)
Other chronic primary headache or orofacial pain 
(Temporomandibular joint disorder, chronic primary orofacial 
pain [atypical face pain]) (M26.60, G50.1)
Low Should not be considered Strong Consensus 
(14/14; 9/9)
Functional somatic disorders (e.g. fibromyalgia syndrome, 
irritable bowel syndrome) (M79.70; F45.32/K58.0/K58.1)
Low Should not be considered Consensus/strong 
Consensus (14/15; 
9/9)
Other chronic primary visceral pain syndromes (Chronic 
primary chest pain [atypical chest pain], chronic primary 
epigastric pain syndrome [functional dyspepsia], chronic 
primary bladder pain syndrome [overactive bladder], chronic 
primary pelvic pain syndrome [pelvic and perineal pain] 
(R07.89. K30, N32.81, R102.]
Low Should not be considered Strong Consensus 
(14/14; 9/9)
Chronic primary musculoskeletal pain syndromes (cervical, 
thoracic, low back, limb pain) (no corresponding ICD- 10 codes 
available)
Low Should not be considered Consensus/strong 
Consensus (14/15; 
9/9)
Chronic pain as a major manifestation of a mental disorder 
(atypical depression, persistent somatoform pain disorder, 
generalized anxiety disorder, post- traumatic stress disorder) 
(F41, F43, F32, F33, F45)
Low Should not be considered Strong Consensus 
(15/15; 10/10)
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et al., 2020). This subgroup of patients may have a high poten-
tial for substance use disorders and opioids – if prescripbed 
– shall be used with high level of control and attention.
Inflammatory bowel diseases: Long- lasting pain is seldom a 
problem in patients with ulcerative colitis unless severe compli-
cations occur, but patients with Crohn's disease may suffer from 
severe chronic pain due to inflammation, strictures and steno-
sis of the gut. In a US cohort study, patients reported the same 
intensity of abdominal pain with and without opioids (Coates 
et al., 2020), but this may reflect confounding by indication as 
opioids are likely administered to patients with most pain and 
the study had a retrospective design. In a British retrospective 
cohort study, mortality was increased in case of high or moder-
ate morphine dosage compared to propensity matched controls 
(Burr et al., 2018). The problems with visceral pain and opioids 
are mainly related to their side- effects on the gut and problems 
with motility, fluid transport and sphincter function (Farmer 
et  al.,  2019). This is often a major problem in patients with 
Crohn's disease where strictures and stenosis of the gut may 
worsen the opioid induced side effects. To summarize, opioids 
can be considered for short- term treatment of pain in case of 
acute flare- ups in patients with Crohn's disease, but long- term 
opioid use may be associated with poor outcomes. The guide-
line of the British Society of Gastroenterology discourages the 
use of opioids for pain management in inflammatory bowel dis-
eases (Lamb et al., 2019).
3.1.2 | Part 2: Good clinical practice
1. Measures prior to opioid initiation
1.1 Case history and clinical status: General case history 
(including previous substance use disorder), pain- related 
case history and the physical and psychological status of the 
patient should be considered and documented. Good clinical 
practice statement. Strong Consensus (17/17; 17/17).
Practice tool (Facultative): Brief Pain Inventory Short 
Version: http://www.npcrc.org/files/ news/brief pain_short.pdf
1.2 Screening for mental disorders: The physician who 
is thinking about opioid prescribing should consider docu-
mentation of psychosocial case history and screening for cur-
rent and/or past psychiatric disorders. Good clinical practice 
statement. Strong Consensus (17/17; 17/17).
Practice tool (Facultative): Patient Health Questionnaire 
4. https://www.orego npain guida nce.org/app/conte nt/uploa 
ds/2016/05/PHQ- 4.pdf
1.3 Mental health care examination: In the case of in-
dications of a mental disorder (depressive and anxiety dis-
orders, substance use disorder) it should be considered to 
offer the patient a consultation with a mental health care 
specialist depending on local resources and tradition. Good 
clinical practice statement. Strong Consensus (17/17; 
17/17).
Rationale: Mental health disorders increase the risk of 
abuse of prescribed opioids (Cragg et al., 2019).
1.4 Therapeutic goals. Physicians prescribing opioids 
should consider setting individual and realistic therapeutic 
goals together with the patient. Good clinical practice state-
ment. Strong Consensus (17/17; 17/17).
Rationale: The definition of therapeutic goals includes the 
consideration of the patients belief system regarding the ef-
ficacy of opioids. Patients with CNCP may have unrealistic 
expectations for medication- based pain relief, for example, 
complete pain relief. From a medical point of view, reason-
able therapeutic goals (= therapeutic response) are individ-
ually meaningful improvements in everyday function (e.g. 
return to work, ‘being able to mow the lawn again’, ‘be able 
to take care of oneself again’). Goals may also include pain 
relief of 30% or greater, although pain reduction as a thera-
peutic goal has been the topic of some debate (Ballantyne & 
Sullivan, 2015).
1.5 Patient information: Physicians prescribing opioids 
should consider providing patients with information by 
means of documented oral or written communication, includ-
ing information on traffic and workplace aspects relevant to 
the patient (and potentially to the family and/or caregiver). 
Good clinical practice statement. Strong Consensus (17/17; 
17/17).
Comment: Information is likely to work best is it is easily 
understood by patients and brief.
Patient information may include:
• Instructions relating to exact timing and dosage of medica-
tion; duration of action of the medication; instructions to 
follow in case of a missed dose
• Indications of interactions with other medications includ-
ing over- the – counter medication and illicit substances
• Prophylactic treatment of adverse medication reactions, 
such as constipation
• Cessation of alcohol or sedative consumption without prior 
discussion with the physician
• Patient responsibilities, such as good adherence to the 
treatment plan, regular feedback to the treating physician; 
for example, in the form of a pain journal
• Safe storage of opioids
• Instructions on how to safely dispose of opioids not used 
by the patient in accordance with the relevant legal regula-
tions on narcotics
• Legal aspect pertaining to distribution of opioid- containing 
medications
• Taking opioid- containing medications abroad
• Possible negative influence on the ability to drive, as well 
as on activities in the workplace (e.g. work with machines, 
control activities), and during leisure time (e.g. housework, 
gardening, sport)
• Potential short- and long- term harms
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Comment: Patients should be informed that driving under 
stable doses of opioids may not be impaired in general and that 
patient's has the responsibility checking himself a priori, if he 
feels fit for driving or not. Information on the impact of impair-
ment due to other health- related conditions (such as mental dis-
eases, motor function impairment) and co- medication (such as 
benzodiazepines, antidepressive medications) must also be pro-
vided. Meta- analysis of experimental studies have shown that 
there are many factors influencing the degree of impairment 
caused by medication consumption (e.g. active agent, galen-
ics, route of administration, dose, time of administration, time 
period between administration and performance requirement, 
compliance and disposition of the patient as well as concom-
itant use of additional medications) (Ramaekers et al., 2006).
1.6 Titration and driving safety: Physicians prescribing 
opioids should consider informing patient of national legal 
regulations regarding driving during the titration phase or 
when their dose is changed and to document the informa-
tion in the chart. Good clinical practice statement. Strong 
Consensus (17/17; 17/17).
Comment: Titration/opioid initiation phase including 
dose change (upwards, downwards) or opioid switching are 
the most vulnerable phases of functional/cognitive impair-
ment due to opioid treatment (Bruera et al., 1989; Ramaekers 
et al., 2006).
2. Treatment with opioids
2.1 Number of prescribing physicians: Physicians pre-
scribing opioids can consider opioid prescriptions only by 
one physician at a time when possible or by a physician of the 
same clinical team or a nominee if the designated prescriber 
is on leave. Strong Consensus (16/16;11/11).
Comment: Prescription by multiple physicians is associ-
ated with abuse and dependence of prescribed opioids (Cragg 
et al., 2019).
2.2 Titration: Physicians prescribing opioids should con-
sider initiating treatment with low doses (<50 mg morphine 
equivalent/d). Good clinical practice statement. Consensus/
strong Consensus (15/16;11/11).
Comment: There are different practice tools available for 
calculating morphine milligram equivalents (MME). They 
differ in the dosages of MME based on single dose studies 
in healthy individuals and can vary considerably. Therefore, 
these practice tools should be used as a guide only. When 
changing from one opioid to another, conversion ratios 
should always be used cautiously.
Practice tool: Calculating morphine milligram equivalents.
https://www.cdc.gov/drugo verdo se/train ing/dosin g/
app: http://www.opioi dcalc ulator.com.au/
2.3 Titration: Physicians prescribing opioids should con-
sider increasing doses in a stepwise manner in order to reach 
the individual therapeutic goal- depending on effectiveness 
and tolerability. Good clinical practice statement. Strong 
Consensus (16/16;11/11).
Comment: A stepwise manner could be 25% increase 
within 3– 8 days.
2.4 Treatment responders and optimal dose: Physicians 
and patients should consider that an optimal dose is one 
which achieves the predefined therapeutic goals with simul-
taneous minimal or tolerable adverse events (=treatment re-
sponder). Good clinical practice statement. Strong Consensus 
(17/17;12/12).
Comment: An optimal dose is reached when an increase 
does not lead to any pain reduction or functional improvement.
2.5 Maximum dosage: We suggest exceeding a dose of 
>90 mg/d oral MME in exceptional cases only. Weak recom-
mendation. Consensus/strong Consensus (14/17; 12/12)
Rationale: Observational studies conducted in North 
America provide evidence of a progressive increase in the 
likelihood of unintentional non- fatal overdose or death as the 
prescribed dose of opioids increases. These serious outcomes 
are rare in those prescribed less than 50 MEQ/d, but increase 
in those prescribed doses of 50– 90 MEQ/d, and though still 
rare, are further increased in those prescribed doses over 90 
MEQ/d (Busse et al., 2017).
Evidence summary:
PICO
Population: Patients with chronic noncancer pain beginning 
opioid therapy Intervention: Limit opioid dose to a particular 
maximum dose. Comparator: No maximum opioid dose.
Meta- regression of within- trial comparisons of different 
doses of opioids found moderate- quality evidence against a 
dose- response effect for pain relief or functional recovery 
(Busse et al. 2017).
The daily dosages in the long- term open label exten-
sions studies were as follows: Buprenorphine transdermal 
(5– 40 µg/h; average 14 µg/h); Hydromorphone (8– 32 mg/d; 
average 17 mg/d); Morphine (Maximum 90 mg/d, half of the 
patients used <60 mg/d); Oxycodone: 20– 140 mg/d (mean 
dosages in studies 44 mg/d); Tapentadol (100– 500 mg/d; av-
erage 368 mg/d) (Bialas et al., 2020).
There is likely a dose- dependent increase in the risk of 
non- fatal opioid overdose: 0.2% for <20  mg MED/day; 
0.7% for 50– 99 mg MED/day; and 1.8% for ≥100 mg MED/
day. There is an increased risk of fatal opioid overdose with 
higher doses: 0.1% for <20  mg MED/day; 0.14% for 20– 
49 mg MED/day; 0.18% for 50– 99 mg MED/day; and 0.23% 
for ≥100 mg MED/day (Busse et al., 2017). Confounding by 
indication (more severe cases receive higher dosages of opi-
oids) have to be taken into account in the studies showing a 
dose- dependent increase of risks (Ranapurwala et al., 2019).
Based on these data, current guidelines recommend a 
clinical re- evaluation of the following dosage are exceeded: 
France and Germany: >120 mg MEQ/d (France: Specialist 
consultation >150 mg MEQ/d) (Häuser et al., 2020; Moisset 
& Martinez, 2016) and USA and Canada >90 MEQ/d (Busse 
et al., 2017; Dowell et al., 2016).
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There is wide variability in patient response to pain 
medications, which may be related to pain origin, pain 
sensitivity, cultural differences, weight, age and prior use 
of opiates, as well as genetic polymorphisms. Medication- 
metabolizing enzymes are commonly influenced by genetic 
variations. The CYP450 enzymes, CYP3A4 (fentanyl) 
and CYP2D6 (codeine, hydrocodone, oxycodone, trama-
dol) are involved in the metabolism of opioids (Agarwal 
et al., 2017). Some patients (e.g. rapid metabolizers) might 
require higher dosages of opioids than the ones recom-
mended by the guidelines.
This recommendation does not address or suggest discon-
tinuation of opioids already prescribed at higher dosages nor 
to justify abruptly stopping opioid prescriptions or coverage.
2.6 Opioid rotation. In case of inadequate pain relief or 
intolerable opioid- related toxicity/adverse effects, a switch 
to an alternative opioid (opioid rotation) should be consid-
ered. Good clinical practice statement. Consensus/strong 
Consensus (14/15; 10/10).
Comment: The evidence to support the practice of opioid 
switching is largely anecdotal or based on observational and 
uncontrolled studies (Treillet et al., 2018). For details of opi-
oid rotation see Figure 1 and Supplementary Material 6.
2.7 Indication for potential long- term opioid therapy: 
A therapy lasting >3  months should only be considered 
in treatment responders (as defined in Part 2, Section 1.4 
above). Good clinical practice statement. Consensus/Strong 
Consensus (16/17; 12/12).
Comment: The decision to continue or stop opioid therapy 
should occur at 1 month in the majority of patients. In some 
patients, this decision may occur up to 3 months following 
opioid initiation, for example, in case of a very slow increase 
in dosage over time.
3. Monitoring and documentation of treatment
3.1 Regular monitoring of treatment: During LTOT, pre-
scribing physicians should consider to review the following 
at regular intervals (at least once every three months): (1) 
whether therapeutic goals continue to be met, (2) whether 
there are indications of adverse events (e.g. loss of libido or 
psychological changes such as loss of interest, hypomnesis or 
falls), or (3) evidence of opioid use disorder or non- medical 
use. Good clinical practice statement. Strong Consensus 
(17/17; 12/12).
3.2 Urine drug screening: Urine drug screening should be 
considered when there is suspected non- medical use of pre-
scribed opioids and/or illicit drug use. Good clinical practice 
statement. Strong Consensus (17/17; 12/12).
Comment: Consider screening for the following sub-
stances: Amphetamines, methamphetamines, benzodiaze-
pines, barbiturates, marijuana, cocaine and phencyclidine.
4. Discontinuation of treatment with opioids
4.1 Discontinuation of an opioid trial (<12  weeks): 
If the individual therapeutic goals are not met during the 
titration phase (maximum 12  weeks) or after rotation to 
another opioid or if insufficiently treatable or intolerable 
adverse events occur (in the opinion of patient or physi-
cian), treatment with opioid- containing analgesics should 
be considered for discontinuation in a stepwise manner. 
Good clinical practice statement. Strong Consensus (17/17; 
12/12).
4.2 Discontinuation of treatment >12 weeks
Long- term treatment should be considered for discontinu-
ation in a stepwise manner if:
1. The individual therapeutic goals are no longer achieved, 
or insufficiently treatable or intolerable adverse events 
occur (in the opinion of patient or physician),
2. The individual therapeutic goals are achieved by other 
medical, physiotherapeutic, physical or psychotherapeutic 
treatments.
3. The person prescribed with opioids refuse urine tests for 
medications in case of suspected non- medical use of pre-
scribed opioids.
4. The person prescribed opioids diverts or uses the opioids 
in a non- medical manner despite complementary treat-
ment from a dependence specialist.
F I G U R E  1  Opioid rotation (modified 





2) No major side effects
Non-responders:
1) Pain controlled but side-effects are intolerable 
desite treatment
2) Inadequate analgesia but dose cannot be
increased due to limiting side-effects despite
treatment
3) Inadequate analgesia despite titration, no major 
side effects
Considerations:
1) Is the pain opioid responsive?
2) Other factors causing side-
effects
Opioid rotation:
1) Discontine 1st opioid
2) Calculate total dose including any rescue
medication around-the-clock to oral morphine
equivalents using conversion tables*
3) Reduce equivalent dose of 2nd opioid by 50-75% 
of 1st opioid
4) Start careful titrating
5) Make immediate release opioids available
Considerations:
1) Individual patient factors when second
opioid is selected (age, experience with 
previous exposure, comorbidity, co-
medication, problems with intake etc.)




2) No major side effects
   | 963HÄUSER Et al.
Good clinical practice statement. Strong Consensus 
(17/17; 12/12).
4.2 Medication reduction
After 6  months of opioid treatment with a good re-
sponse, a dose reduction can be considered with the pa-
tient, to assess the indication for continued treatment and 
the response to the non- pharmacological treatments (e.g. 
multimodal therapy) that are being used in parallel. Good 
clinical practice statement. Strong Consensus (17/17; 
12/12).
The main recommendations for good clinical practice are 
summarized in Table 4.
4 |  DISCUSSION
We discuss some similarities and differences between the ex-
isting guidelines, including those from Canada, the US CDC 
and the European clinical practice recommendations.
Scope and audience: All existing guidelines aim to pro-
mote responsible prescribing of opioids to promote the safety 
of people with chronic pain. All papers covers CNCP, al-
though the title of the CDC guideline is ‘chronic pain’. The 
Canadian and CDC guidelines are valid for adults with CNCP, 
while the European recommendations also include children 
and adolescents. The Canadian guidelines were revised and 
the CDC guidelines were developed to reduce the opioid ep-
idemic in Canada and USA. The European recommendations 
were drafted to help prevent a prescription opioid epidemic 
in Europe. The target audience of the CDC guidelines are 
primary care clinicians, while the Canadian and European 
recommendations are targeted to all health care professionals 
involved in the care of people with CNCP.
Composition of the guideline panel: The Canadian guide-
line was an investigator- initiated study. The US and European 
papers were developed by an umbrella organisation (CDC 
and EFIC, respectively). All guidelines/position papers were 
produced by a group of medical experts of different special-
ties. The European TF included other health professionals 
(e.g. nursing, clinical psychology). Canada and Europe in-
cluded a patient representative in the steering committee and 
several measures of patient engagement. Canada and Europe 
included experts who viewed opioids as having an important 
role and several who viewed the practice with skepticism.
Engagement of other organisations and reviews: The 
Canadian guideline group included the input of two Canadian 
medical associations for clinical practice statements. CDC 
invited federal partners and stakeholders to comment. The 
European recommendations were approved by scientific or-
ganizations of different health care professionals. All guide-
lines/recommendations were open to public comments. The 
European recommendations invited European as well as 
North American medical experts to review.
Managing conflicts of interest: All papers required a con-
flict of interest statement of all members of the guideline 
panel. CDC excluded experts who had a financial or pro-
motional relationship with a company that made a product 
that might be affected by the guideline. The potential im-
pact of financial COIs in European recommendations can be 
T A B L E  4  Opioids for chronic noncancer pain – a summary
1. Comprehensive clinical evaluation
a. Medical and psychosocial history
b. Medical and if necessary psychological and physiotherapeutic 
examination
c. Technical examinations
d. Interdisciplinary assessment if needed
2. Start treatment
a. Education
b. Non- pharmacological therapies
c. Non- opioids if needed
3. Consider a trial with opioids if
a. There is a relative indication for opioids for the type of the 
pain syndrome of the patient and
b. non- pharmacological treatment and non- opioid analgesics are
(i)    Not effective and/or
(ii)  Not tolerated and/or
(iii) Contraindicated
4. Shared decision making with patients
a. Assess individual benefit risk- ratio
b. Consider patient's treatment preferences
c. Obtain informed consent and agreement
d. Establish individual and realistic treatment goals (sustained 
improvement of daily functioning, pain reduction)
5. Initial dose adjustment phase (8– 12 weeks)
a. Start slow, go slow
b. Monitor and treat side effects if needed
c. Find the optimal dosage (predefined treatment goals met; no 
or tolerable/manageable side effects)
d. Discontinue if
(i)    Predefined treatment goals not reached
(ii)  Intolerable/manageable side effects
(iii) Non- medical use of prescribed opioids
6. Long- term opioid therapy (>12 weeks)
a. Regular assessments (at least every 3 months)
b. Assess four A's: Activity, analgesia, aberrant behaviour, 
adverse effects
c. Promote non- pharmacological therapies
d. Continue if
(i)    Stable dosage
(ii)   Sustained improvement of daily functioning and pain 
reduction
(iii) tolerable/manageable side effects
(iv) No signals of non- medical use of prescribed opioids
e. Discuss tapering/drug holiday after 6 months with the patient
f. Discontinue if
(i)    Dose escalation
(ii)   Loss of improvement of daily functioning and of pain 
reduction
(iii) tolerable/manageable side effects
(iv) Signals of non- medical use of prescribed opioids
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concluded from the strength of consensus separately assessed 
for the whole guideline group and the ones without financial 
COIs. CDC reviewed potential nonfinancial conflicts care-
fully (e.g. intellectual property, travel, public statements or 
positions such as congressional testimony) to determine if the 
activities would have a direct and predictable effect on the 
recommendation.
Methods: All guidelines/recommendations conducted 
systematic searches of literature, performed meta- analyses of 
randomized placebo- controlled trials with opioids and rated 
the quality of evidence. The European guidelines assessed 
the strength of consensus on recommendations and clinical 
practice statements of the TF. EFIC's strong consensus for 
GCP and lack of strong consensus on most potential indi-
cations and contraindications reflect the different clinical 
background and experience with opioids for CNCP of the TF 
members. All guidelines/recommendations used GRADE to 
rate the quality of evidence for evidence- based recommen-
dations. The majority of the European guidances for clini-
cians were based on a selective search of literature and expert 
consensus.
Overall content: Canada produced 10, CDC 12 and Europe 
six evidence- based recommendations. Canada offered 10 evi-
dence – based expert guidances and Europe 60 good clinical 
practice statements.
Role of opioids in the management of CNCP: All guide-
lines/recommendations recommended to start a trial with 
opioids only if non- pharmacological and non- opioid medi-
cations have failed. The European recommendations speci-
fied that established (guideline- recommended) treatments 
should have failed. The belief that opioids are the most pow-
erful medication against CNCP have not been supported by 
any of the three guidelines, which demonstrated that opioids 
and non- opioid analgesics are equally effective in reducing 
pain (with small effect sizes). Therefore, the World Health 
Organization's analgesic ‘ladder’ for cancer- pain treat-
ment, which placed nonsteroidal anti- inflammatory drugs 
(NSAIDs) on the bottom rung for mild pain and opioids on 
higher rungs for persistent moderate- to severe pain, is not 
supported in CNCP.
In contrast to the North American guidelines, the 
European recommendations gave different recommen-
dations for different types of CNCP, for example, not 
to treat primary chronic pain syndromes with opioids. 
Prescription of high doses of opioids to patients with pri-
mary pain syndromes might have been a factor driving 
the opioid crisis in North America. Inclusion of patients 
with physical and psychological trauma, social disadvan-
tage, and hopelessness that can enhance reports of pain 
intensity may have also resulted in prescription of more 
opioids (Dasgupta et  al.,  2018; deWeerdt,  2019; Petzke 
et al., 2020).
All three papers defined stopping rules for opioid therapy.
5 |  CONCLUSIONS
Opioids are not a panacea for all types of CNCP, and must 
only be used in selected and supervised pain patients as part 
of a comprehensive, multi- modal, multi- disciplinary ap-
proach to treatment. In this context alone, opioid therapy 
can be a useful tool in achieving and maintaining an optimal 
level of pain control in selected patients. Misplaced barriers 
to access (e.g. payers restricting reimbursement or requiring 
previous authorizations that lead to lengthy delays) can lead 
to unnecessary suffering, just as overly- zealous prescription 
of opioids can lead to unnecessary suffering.
As recently stated by Barnett (2020), “the opioid- 
prescribing debate seems hopelessly polarized: either opi-
oids are industrially sponsored weapons of mass addiction 
or they‘re a misunderstood last hope for alleviating suffer-
ing. The optimal use of medications lies between these two 
poles.”
Opioids are a two edged sword. Used inappropriately 
(wrong indication, inappropriate monitoring of positive and 
negative effects, inadequate management of side effects) 
they can be associated with relevant harms to the patient. 
Therefore, the European Pain Federation calls for continu-
ous medical education on the correct use of opioids in multi- 
professional and multi- modal therapeutic approaches. We 
also call for enhancing access to, and funding for, compre-
hensive pain treatment services and therapies and increasing 
funds for robust research in pain treatment.
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